AG
CRVS icon

Algert Global’s Corvus Pharmaceuticals CRVS Stock Holding History

Algert Global’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,949
Closed -$72K – 998
2021
Q3 		$72K Sell
14,949
-4,788
-24% -$14.2K 0.01% 989
2021
Q2 		$53K Sell
19,737
-23,120
-54% -$63.7K 0.02% 411
2021
Q1 		$132K Buy
42,857
+27,390
+177% +$98.9K 0.04% 396
2020
Q4 		$55K Buy
15,467
+4,220
+38% +$17K 0.02% 393
2020
Q3 		$45K Buy
+11,247
New +$44.9K 0.01% 379
2020
Q2 		– Sell
-16,947
Closed -$36K – 436
2020
Q1 		$36K Buy
+16,947
New +$68.8K 0.02% 387

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return